article · BMC Cancer
A retrospective observational study examined care gaps and survival outcomes for 163 colorectal cancer patients treated at a cancer centre in Northern Rwanda between 2012 and 2018. Most patients presented with rectal cancer and localised disease, with a cohort median age of 53 years. Overall, 68 percent received chemotherapy and 45 percent underwent primary surgical resection. Primary surgical resection for curable disease was notably lower for rectal cancer at 40 percent compared to 91 percent for colon cancer, and only about a quarter of curable rectal cancer patients received radiotherapy. Median overall survival across the cohort was 3.68 years, while median disease-free survival for localised cases was 2.21 years. Poorer overall survival was associated with male sex and metastatic disease, while rectal cancer was linked to worse disease-free survival.
Colorectal cancer contributes substantially to cancer deaths in sub-Saharan Africa, yet clinical data from the region remain scarce. Documenting specific shortfalls in access to surgery and radiotherapy provides essential evidence for oncology programmes and health planners. These findings clarify survival determinants in resource-constrained environments, helping identify priority areas for strengthening multidisciplinary cancer care infrastructure.
The abstract does not indicate an application pathway.
AI-generated from the published abstract. Always read the original work before citing.
Colorectal cancer (CRC) is a significant contributor to cancer mortality in sub-Saharan Africa, yet it remains understudied. This study describes care gaps and survival outcomes of CRC in Rwanda. This was a retrospective observational cohort study. We included patients treated at Butaro Cancer Center of Excellence, a tertiary cancer center in Northern Rwanda. 163 patients with CRC who presented between July 2012 and June 2018 were included. Comprehensive data were collected on patient characteristics; diagnostic workup; treatment gaps; and survival outcomes up to August 2023. The main outcome measures were five-year overall survival (OS) for the entire cohort, and disease-free survival (DFS) for patients with localized disease; these were estimated using the Kaplan-Meier method. Exploratory multivariate survival analysis examined the associations between patient/disease characteristics and survival. The cohort median age was 53 years; 86 (53%) were females and 127 (78%) had rectal cancer. Most patients (98, 60%) had localized disease. Overall, 111 (68%) patients received chemotherapy, and 74 (45%) received primary surgical resection. Of those treated with curative intent, rate of primary surgical resection was higher in colon cancer (20, 91%) compared to rectal cancer (38, 40%). Only 24 (25.5%) patients with curable rectal cancer received radiotherapy. The median OS was 3.68 years, while the median DFS of patients with localized disease was 2.21 years. Gender and stage were associated with OS, but not disease location or age. For OS, compared to female patients, males had an adjusted hazard ratio (aHR) of 1.84 ( p = 0.007), while patients with metastatic disease had an aHR of 1.92 ( p = 0.004). Only disease location was associated with DFS, with an aHR of 2.35 ( p = 0.047) for rectal versus colon cancer. Multidisciplinary CRC treatment remains a challenge in Rwanda, similar to other low-resource settings. Our results highlight striking gaps in care, across all treatment modalities and particularly low rates of surgery and radiation. Not applicable.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12885-026-16799-1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
